[Consensus and peg-interferon in chronic hepatitis C. Therapy for refractory cases?].
Kaiser
S
S
Medizinische Klinik I, Eberhard-Karls-Universität Tübingen.
D000998:Antiviral Agents / Q000009:adverse effects; D002986:Clinical Trials as Topic; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins; D017211:Treatment Failure
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C050739:interferon alfacon-1; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a